MEDICINA
Departamento
Verónica
González de la Calle
Investigadora desde null
Publicaciones en las que colabora con Verónica González de la Calle (44)
2023
-
Clonal architecture and evolutionary history of Waldenström's macroglobulinemia at the single-cell level
Disease models & mechanisms, Vol. 16, Núm. 8
-
Definition and Clinical Significance of the Monoclonal Gammopathy of Undetermined Significance-Like Phenotype in Patients With Monoclonal Gammopathies
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 41, Núm. 16, pp. 3019-3031
-
Fractionated initial infusion and booster dose of ARI0002h, a humanised, BCMA-directed CAR T-cell therapy, for patients with relapsed or refractory multiple myeloma (CARTBCMA-HCB-01): a single-arm, multicentre, academic pilot study
The Lancet Oncology, Vol. 24, Núm. 8, pp. 913-924
-
Lenalidomide maintenance based on a genetic profile
Blood
-
Multiple myeloma with t(11;14): impact of novel agents on outcome
Blood Cancer Journal, Vol. 13, Núm. 1
-
Novel Agents as Main Drivers for Continued Improvement in Survival in Multiple Myeloma
Cancers, Vol. 15, Núm. 5
-
Randomized phase II study of weekly carfilzomib 70 mg/m2 and dexamethasone with or without cyclophosphamide in relapsed and/or refractory multiple myeloma patients
Haematologica, Vol. 108, Núm. 10, pp. 2753-2763
2022
-
Anti-BCMA CAR T-cell Therapy: Changing the Natural History of Multiple Myeloma
HemaSphere
-
Interlaboratory Analytical Validation of a Next-Generation Sequencing Strategy for Clonotypic Assessment and Minimal Residual Disease Monitoring in Multiple Myeloma
Archives of pathology & laboratory medicine, Vol. 146, Núm. 7, pp. 862-871
-
MM-198 Anti-BCMA Therapy in Multiple Myeloma: A Single-Center Experience
Clinical Lymphoma, Myeloma and Leukemia, Vol. 22, pp. S413
-
MM-202 Impact of t(11;14) in Multiple Myeloma on Response to Treatment and Survival
Clinical Lymphoma, Myeloma and Leukemia, Vol. 22, pp. S413-S414
-
MYD88 Mutations: Transforming the Landscape of IgM Monoclonal Gammopathies
International Journal of Molecular Sciences, Vol. 23, Núm. 10
-
Mass spectrometry vs immunofixation for treatment monitoring in multiple myeloma
Blood Advances, Vol. 6, Núm. 11, pp. 3234-3239
-
Monoclonal gammopathy of renal significance (MGRS): Real-world data on outcomes and prognostic factors
American Journal of Hematology, Vol. 97, Núm. 7, pp. 877-884
-
Prevention of venous thromboembolism in hematologic neoplasms: an expert consensus from SEHH–SETH
Clinical and Translational Oncology, Vol. 24, Núm. 5, pp. 770-783
-
Recovery of polyclonal immunoglobulins during treatment in patients ineligible for autologous stem-cell transplantation is a prognostic marker of longer progression-free survival and overall survival
British Journal of Haematology, Vol. 198, Núm. 2, pp. 278-287
2021
-
6q deletion in Waldenström macroglobulinaemia negatively affects time to transformation and survival
British Journal of Haematology, Vol. 192, Núm. 5, pp. 843-852
-
Dexamethasone as a partner of isatuximab
Blood
-
Genetic complexity impacts the clinical outcome of follicular lymphoma patients
Blood Cancer Journal
-
High-risk multiple myeloma: how to treat at diagnosis and relapse?
Hematology (United States), Vol. 2021, Núm. 1, pp. 30-36